# A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Study · id `cardio:ct-nct04252287` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04252287](<https://clinicaltrials.gov/study/NCT04252287>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04252287

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

## Technical summary

Registry record NCT04252287. Randomized; double masking; primary purpose treatment. Start 2020-03-10 (actual); primary completion 2021-11-09 (actual). Results posted on 2023-01-12.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 476 participants (enrolled count; ClinicalTrials.gov record NCT04252287, source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)
- Started: 2020-03-10 (actual) (ClinicalTrials.gov record NCT04252287, source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)
- Primary completion: 2021-11-09 (actual) (ClinicalTrials.gov record NCT04252287, source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)
- Completion: 2021-11-09 (actual) (ClinicalTrials.gov record NCT04252287, source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)
- Results first posted: 2023-01-12 (ClinicalTrials.gov record NCT04252287, source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04252287, source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04252287-2025-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
- Acronym: CHIEF-HF
- Condition: Heart Failure
- Intervention (Drug): Canagliflozin 100 mg
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial (`cardio:pubmed-35228753`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial (`cardio:pubmed-37040839`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure (`cardio:pubmed-37498273`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin (`cardio:pubmed-38385941`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cbc223a1b653696262e51439bd04845f6bd13d5a44739cc0c6b1907e5416012e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
